Literature DB >> 1569425

Power and weakness of spontaneous reporting: a probabilistic approach.

P Tubert1, B Bégaud, J C Péré, F Haramburu, J Lellouch.   

Abstract

It has been clearly demonstrated that spontaneous reporting remains one of the best ways for picking up new adverse drug reactions (ADRs) once a drug is on the market. The probability of revealing a new ADR by spontaneous reporting was studied as a function of reporting rate, strength of drug-event association (relative risk), background incidence of the event and number of patients treated. The model included determination of (i) the probability of reporting at least one drug-event association case and (ii) the overall probability of concluding that the drug-event association is not coincidental. Both probabilities were generally low. The results suggest that the identification of a new risk by spontaneous reporting implies a strong association between the drug treatment and the occurrence of the event.

Entities:  

Mesh:

Year:  1992        PMID: 1569425     DOI: 10.1016/0895-4356(92)90088-5

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  15 in total

1.  Use of measures of disproportionality in pharmacovigilance: three Dutch examples.

Authors:  Antoine C G Egberts; Ronald H B Meyboom; Eugène P van Puijenbroek
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

2.  Risk of drug-induced agranulocytosis: the case of calcium dobesilate.

Authors:  Pedro Zapater; José Francisco Horga; Antonio García
Journal:  Eur J Clin Pharmacol       Date:  2003-02-19       Impact factor: 2.953

Review 3.  Detection, verification, and quantification of adverse drug reactions.

Authors:  Bruno H Ch Stricker; Bruce M Psaty
Journal:  BMJ       Date:  2004-07-03

4.  HMG CoA reductase inhibitors and impotence: two case series from the Spanish and French drug monitoring systems.

Authors:  Alfonso Carvajal; Diego Macias; María Sáinz; Sara Ortega; Luis H Martín Arias; Alfonso Velasco; Haleh Bagheri; Maryse Lapeyre-Mestre; Jean-Louis Montastruc
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

5.  Detection and incidence of drug-induced agranulocytosis in hospital: a prospective analysis from laboratory signals.

Authors:  N Tavassoli; E Duchayne; B Sadaba; K Desboeuf; A Sommet; M Lapeyre-Mestre; M J Muoz; P Sie; J Honorato; J L Montastruc; H Bagheri
Journal:  Eur J Clin Pharmacol       Date:  2007-01-17       Impact factor: 2.953

6.  Simulating adverse event spontaneous reporting systems as preferential attachment networks: application to the Vaccine Adverse Event Reporting System.

Authors:  J Scott; T Botsis; R Ball
Journal:  Appl Clin Inform       Date:  2014-03-05       Impact factor: 2.342

7.  Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.

Authors:  Lois La Grenade; Lauren Lee; Joyce Weaver; Renan Bonnel; Claudia Karwoski; Laura Governale; Allen Brinker
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

8.  Detection and incidence of drug-induced liver injuries in hospital: a prospective analysis from laboratory signals.

Authors:  H Bagheri; F Michel; M Lapeyre-Mestre; E Lagier; J P Cambus; P Valdiguié; J L Montastruc
Journal:  Br J Clin Pharmacol       Date:  2000-11       Impact factor: 4.335

9.  Detection and incidence of muscular adverse drug reactions: a prospective analysis from laboratory signals.

Authors:  A Dugué; H Bagheri; M Lapeyre-Mestre; J F Tournamille; L Sailler; G Dedieu; R Salvayre; J P Thouvenot; P Massip; J L Montastruc
Journal:  Eur J Clin Pharmacol       Date:  2004-04-28       Impact factor: 2.953

10.  Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin.

Authors:  Allen Brinker; Lawrence Goldkind; Renan Bonnel; Julie Beitz
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.